Private equity sector company, HgCapital Trust (HGT), has indirectly invested a further £8.1m in Evaluate alongside other institutional clients of its manager, Hg. Hg is a leading European software investor

‘A leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry’

Evaluate is described as a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry.

The announcement goes on to note: “Hg will now become the majority shareholder in Evaluate. Hg’s backing will help Evaluate to continue to build out capabilities that support pharmaceutical portfolio optimisation and R&D productivity, accelerating investment in innovation and data science capabilities. It will also enable options for further expansion.”

Deborah Kobewka, CEO at Evaluate, said: “I’m thrilled that Hg will become the majority shareholder at Evaluate. It shows confidence in the company’s trajectory and allows us to drive the business forward to new levels of growth and expansion, which only increases the value and service Evaluate delivers to clients. The opportunities ahead for Evaluate and our clients are greater than ever, especially as we push further into predictive analytics to revolutionise the pharmaceutical industry’s approach to strategic portfolio optimisation.”

HGT: HgCapital Trust’s manager becomes majority shareholder in Evaluate